Fragment-Based Drug Discovery

Drug Design: Fragment-Based Drug DiscoveryDrug Design: Fragment-Based Drug Discovery

Traditionally, new drugs are developed by either making small changes to existing drugs or by individually testing thousands of compounds. Both of these methods require many hours of laborious chemical synthesis. However, new techniques are being applied in the drug industry which decrease the cost and time required to discover and develop new drugs. Fragment-Based Drug Discovery Fragment-based drug discovery (FBDD) is a method of discovering new compounds by utilizing fragments that have some degree of binding affinity for a drug target, optimizing those fragments so as to increase their binding affinity, then linking them together to form a lead compound that has high affinity and selectivity for the drug target. Nuclear magnetic resonance (NMR) and x-ray crystallography can be used to analyze the fragments and drug targets in order to create three-dimensional images which can be used to obtain a detailed, visual analysis. This allows developers to get a visual representation of how each fragment binds to the target. It is also useful in identifying the individual binding sites of the target. Fragment-Based Drug Discovery The development of using SAR by NMRis a classic example of FBDD. (Throughout this discussion ABT-737 will be used to illustrate the FBDD process.) This compound has been shown to effectively inhibit the over-expression of which is a protein that is commonly observed to be over-expressed in many types of cancers. It acts an inhibitor of apoptosis and may also contribute to chemotherapy resistance. Bcl-xl inhibition by ABT-737 therefore, allows apoptosis to occur and helps to prevent chemo-resistance. SAR by NMR Structure-activity relationship (SAR) by (NMR) is one tool that is commonly used to design and develop new drugs. This is the process "in which small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together to produce high-affinity ligands." Ligand Screening The first step of FBDD is to expose the potential drug target to a large number of small molecular fragments. This is usually done with a method known as high-throughput screening. High-throughput screening (HTS) is the process of using robotics to perform a large number of chemical tests. HTS is used to quickly identify fragments that have affinity for the target which are then analyzed to understand why they have affinity. Ligand Optimization Once the fragments have been identified, they are then modified to increase their binding affinity. Applying these 3-D structures to the drug design process involves using either structure-based drug design (SBDD) or ligand-based drug design (LBDD). Structure-Based Drug Design Structure-based drug design is utilized when the 3-D structure of a protein, or other drug target, is used to predict drug candidates. A visual representation of the structure allows developers to pinpoint binding sites and more effectively design a drug that will have high affinity for the target. Ligand-Based Drug Design "Ligand-based drug design (LBDD) techniques are applied when the structure of the receptor is unknown but when a series of compounds or ligands have been identified that show the biological activity of the interest." In other words, once it is known how a ligand binds to a protein or any other molecule, new ligands, and eventually drugs, can be designed to bind in a similar manner and get the desired effect. It involves modifying a known ligand to develop another ligand with a higher binding affinity for the target. ABT-737 One example of drug discovery using SAR by NMR includes the development of . This compound has been shown to effectively inhibit the over-expression of which is a protein that is commonly observed to be over-expressed in many types of cancers. It acts an inhibitor of apoptosis and may also contribute to chemotherapy resistance. Bcl-xl inhibition by ABT-737 therefore, allows apoptosis to occur and helps to prevent chemo-resistance. How SAR by NMR was used to develop ABT-737 Three ligands with moderate affinity for Bcl-xl were analyzed using SAR by NMR in order to develop ABT-737. The structural components that allow the ligands to bind to the protein were then linked together to form ABT-737 - the final compound with high-affinity for Bcl-xl. is a 4'-fluoro-biphenyl-4-carboxylic acid. SAR by NMR was used to identify the interactions that this compound forms with Bcl-xl. The fluorobiphenyl system is hydrophobic and its interactions form a around the fluorobiphenyl system. The of Bcl-xl. The carboxylic acid is later substituted with an acyl sulfonamide (shown in compound 2) which provides increased affinity. binds with high affinity to Bcl-xl. The . The substitution of this sulfonamide for the carboxylic acid from compound 1 allows compound 2 to form a much stronger bond with Bcl-xl by bringing the shared acidic proton in closer proximity to GLY 142. The binding affinity of compound 2 for Bcl-xl is greatly reduced in the presence of human serum albumin (HSA). In order to decrease HSA affinity, and therefore increase Bcl-xl affinity, SAR by NMR was used to modify compound 1 by eliminating key binding groups of compound 1 to HSA without affecting Bcl-xl affinity. Modifying compound 2 to reduce HSA affinity Compound 2 has high affinity for Bcl-xl but has an even higher affinity for HSA. For this reason, when HSA is present, compound 2 and similar ligands are more likely to bind to HSA thereby decreasing the amount that can bind with Bcl-xl. In order to decrease the affinity for HSA while maintaining affinity for Bcl-xl, SAR by NMR was used to compare compound 2 with a , which also has high affinity for HSA. It was found that two hydrophobic portions of compound 2 had very strong hydrophobic interactions with HSA. Therefore, these portions were modified with polar substituents to decrease HSA affinity. To decrease hydrophobicity, the fluorobiphenyl system was substituted with a piperazine ring and a 2-dimethylaminoethyl group was added to the thioethylamino linkage group. Once the components responsible for binding are identified, they can be modified, as in the case of compound 1 where the carboxylic acid was substituted with an acyl sulfonamide, and then they are linked together to create a compound with optimal binding affinity.

spinqualitylabelsall models Bcl-xl in complex with ABT-737 (PDB entry 2yxj) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image